Applicable to all countries, for all new patients and patients already included, and was set up (mainly) to: - Specify that assessments to be carried out by a psychiatrist in the frame of this study were GAD diagnosis - Add the participation of Finland and Slovakia - Comply with German requirement regarding contraceptive methods - Clarify the non-selection criteria : Patients previously not responder to agomelatine, escitalopram or citalopram during the past 12 months whatever the indication were not selected - Add non-selection criteria due to the Escitalopram SmPC update: Known angle-closure glaucoma or history of glaucoma - Specify that concomitant use of medicinal products inducing hypokalaemia/hypomagnesaemia was to be used with caution as it could induce a risk of malignant arrhythmias with Escitalopram (Escitalopram SmPC update) - Allow the use of rescue medication for occasional sleep disorder during the extension period. Occasional intake of hypnotics limited to zolpidem, zopiclone, eszopiclone were allowed after W12 if needed and according to the investigator’s judgment - Specify technical performance of ePRO - Clarify scoring methods of SHAPS - Ensure a more accurate follow-up and analysis of suicidal ideation and behaviour - Harmonize the management of cases of overdose throughout agomelatine studies - Explain that hospitalisation planned before the study and hospitalisation due to social reason were to be reported in the PROCEDURE form of the eCRF - Insert the last versions of THAT, C-SSRS, DSMIV-TR, HAD and SDS scales which have been used by the patients in the study - Correct some mistake/inaccuracy: *Urinary drug screening was done only at selection, not at the end of the study *Harmonization of the selection condition regarding treatment with thyroid hormones and menopause HRT : they could not be started, stopped or modified within the 3 months prior to inclusion visit and not selection visit.

Applicable to all countries for all new patients and patients already included in the 3 month-period. Patients who had reached W24 before approval of this amendment were not concerned. The aim of this amendment was to shorten the optional extension period from a 9-month-period to a 3-month period for all the patients not reaching W24 when the approval for this amendment was obtained (decision taken for strategic reasons from the Sponsor). It allowed to ensure a 6-month treatment period for the patients who were entered in the extension period after approval of the amendment. Patients having already performed W24 visit before this amendment approval were to continue the extension period up to W52. In addition, the interim analysis initially planned was suppressed and all the data were analysed after the end of the study for all patients.